Unlock stock picks and a broker-level newsfeed that powers Wall Street.
It looks like Pfizer, Moderna and J&J vaccines would work against any of these new variants: Dr. Francis Collins , Dir. of NIH

In This Article:

Yahoo Finance’s Editor in Chief Andy Serwer speaks with Dr. Francis Collins, Director of the National Institutes of Health to discuss COVID-19 One Year Later.

Video Transcript

[MUSIC PLAYING]

ANDY SERWER: Back to "Yahoo Finance Live." I'm Andy Serwer, and I'm joined by Dr. Francis Collins, director of the National Institutes of Health. Dr. Collins, great to see you.

FRANCIS COLLINS: Great to see you, Andy. Glad to have a conversation on this significant one-year anniversary.

ANDY SERWER: Yeah. Let's just jump right in, because it has become a one-year anniversary day in the sense that this is the day a year ago where America basically came to realize we had a pandemic and began to shut down. How would you assess where we are right now, Dr. Collins?

FRANCIS COLLINS: Well, it's been a brutal year. Let's be honest about that. 525,000 people lost their lives. I never would have guessed a year ago that it was going to be that bad. And certainly, great harms done to many people's economies as well as the grief and sorrow of lost lives.

We are here now, in March of 2021, on what I would say is a positive trajectory with a lot of encouraging signs now. We're going to approach 100 million people getting injected by the end of this week with a highly safe and effective vaccine. I wouldn't have guessed that would be the case either a year ago. So science has rocketed forward even as we have suffered greatly as a nation.

ANDY SERWER: We spoke 13 months ago, Doctor, and it was February 8. There were less than a dozen cases in the United States at that point, if you imagine. And you said-- and I want to accentuate this one part of this phrase-- "at the present time, there is no reason for considerable anxiety in America," at the present time. So do you remember your thinking changing?

FRANCIS COLLINS: I do. And it began to change shortly after that with the realization that this was a virus that was capable of infecting people who had no symptoms, and some of whom would never get symptoms, others of whom might develop symptoms two or three days later. But this was the worst case you could imagine for a virus that you would try to control with public health measures because you couldn't really know who was spreading it, who was the next super spreader without even being aware that they had it.

We hadn't expected that. That's not the way SARS behaved. That's not the way MERS behaved. But it's the way SARS-COV-2 behaved. And that put us in a much more difficult place in terms of trying to end this pandemic. And frankly, one of our best weapons at that point was the realization we really should be encouraging everybody to get out there and wear masks when you're outside. But we didn't do so well in convincing a lot of people to do so. Let's just say this has been a terribly difficult 12 months of trying to identify the right scientific strategies and then convincing people to take advantage of them.